Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010–2012 Medicare Limited Data Set

Sacks, Naomi; Cyr, Philip L.; Louie, Arthur C.; Liu, Yanmei; Chiarella, Michael; Sharma, Abhishek; Chung, Karen

doi:10.1016/j.clinthera.2018.03.012

Cited by 9 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The costs associated with AML constitute a substantial economic burden [ 35 , 36 ], particularly in older patients who require more frequent hospitalizations and intensive care unit admissions [ 36 ]. According to the UK NICE committee, daunorubicin/cytarabine liposome represents a cost-effective use of health system resources for end-of-life treatments [ 31 ].…”

Section: Place Of Daunorubicin/cytarabine Liposome In the Management mentioning

confidence: 99%

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Blair

2018

Drugs

View full text Add to dashboard Cite

VYXEOS™ is a liposomal-encapsulated formulation of daunorubicin and cytarabine delivering a fixed, synergistic 1:5 molar ratio (hereafter referred to as daunorubicin/cytarabine liposome). Daunorubicin/cytarabine liposome is approved in several countries worldwide for the treatment of adults with therapy-related acute myeloid leukaemia (tAML) and AML with myelodysplasia-related changes (MRC). Approval was based on its clinical benefit in older patients with newly diagnosed high-risk/secondary AML in a pivotal phase III trial. In this study, daunorubicin/cytarabine liposome significantly prolonged overall survival (OS) and event-free survival (EFS) relative to conventional chemotherapy with cytarabine plus daunorubicin (hereafter referred to as 7 + 3). Daunorubicin/cytarabine liposome was also associated with significantly higher rates of complete remission (CR) and CR with incomplete haematological recovery (CRi) compared with 7 + 3. Daunorubicin/cytarabine liposome had an acceptable tolerability profile in older patients with newly diagnosed high-risk/secondary AML. The safety profile of daunorubicin/cytarabine liposome, including types and severities of adverse events, was generally similar to that of 7 + 3. Therefore, daunorubicin/cytarabine liposome is an important treatment option for adults with newly diagnosed tAML or AML-MRC.

show abstract

Section: Place Of Daunorubicin/cytarabine Liposome In the Management mentioning

confidence: 99%

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Blair

2018

Drugs

View full text Add to dashboard Cite

show abstract

“…Thus far, the majority of pharmacoeconomic studies in AML have been conducted in the United States of America (US) [25,26,[28][29][30][31][32], which can be considered a less costeffective health system (14.32% of the gross domestic product (GDP), EUR 7577 per capita) compared to the Spanish healthcare system (6.24% of the GDP, EUR 1617 per capita) [33]. Two USA studies reported higher costs than our study, estimating a mean overall cost of USD 181,538 per patient in a series of 1597 patients with de novo AML or relapsed/refractory (R/R) AML [31], and USD 439,104 in 707 patients with only R/R AML [25].…”

Section: Discussionmentioning

confidence: 99%

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Solana-Altabella

Megías‐Vericat

Ballesta-López

et al. 2022

Cancers

View full text Add to dashboard Cite

Background: Information regarding the impact on healthcare systems of secondary acute myeloid leukemia (sAML) is scarce. Methods: A retrospective review of medical charts identified patients aged 60–75 years with sAML between 2010 and 2019. Patient information was collected from diagnosis to death or last follow-up. Outpatient resource use, reimbursement, frequency and duration of hospitalization, and transfusion burden were assessed. Forty-six patients with a median age of 64 years were included. Anthracycline plus cytarabine regimens were the most common induction treatment (39 patients, 85%). The ratio of the total days hospitalized between the total follow-up was 29%, with a sum of 204 hospitalizations (average four/patient; average duration 21 days). The total average reimbursement was EUR 90,008 per patient, with the majority (EUR 77,827) related to hospital admissions (EUR 17,403/hospitalization). Most hospitalizations (163, mean 22 days) occurred in the period before the first allogeneic hematopoietic stem cell transplant (alloHSCT), costing EUR 59,698 per patient and EUR 15,857 per hospitalization. The period after alloHSCT (in only 10 patients) had 41 hospitalizations (mean 21 days), and a mean reimbursement cost of EUR 99,542 per patient and EUR 24,278 per hospitalization. In conclusion, there is a high consumption of economic and healthcare resources in elderly patients with sAML receiving active treatments in Spain.

show abstract

“…This result must be interpreted with caution, as there are differences in baseline characteristics, with generally higher ages and higher unmarried rates, in patients without chemotherapy. It has been reported that patients who receive chemotherapy are generally younger and have fewer comorbidities and better health [44][45][46].…”

Section: Discussionmentioning

confidence: 99%

“…Of the 64,679 patients diagnosed with acute myeloid leukemia (AML) between 1973 and 2015, 68.48% (44,292) received chemotherapy, and 31.52% of patients (20,387) did not receive chemotherapy (Table 1). Patients who received chemotherapy were generally younger at diagnosis, with an average age of diagnosis of 54 years, compared with those in the nonchemotherapy group (average age: 73 years old).…”

Section: Baseline Characteristicsmentioning

confidence: 99%

Long-term cardiac-specific mortality among 44,292 acute myeloid leukemia patients treated with chemotherapy: a population-based analysis

Zhou

Yang

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is a common hematological malignancy treated with regimens containing anthracycline, an agent with cardiotoxicity. However, the cardiac-specific mortality in AML patients receiving chemotherapy remains unknown. Methods: In this population-based study, patients diagnosed with AML between 1973 and 2015 were identified in the Surveillance, Epidemiology, and End Results database. Cumulative mortality by cause of death was calculated. To quantify the excessive cardiac-specific death compared with the general population, standardized mortality ratios (SMRs) were calculated. Multivariate Cox regression analyses were performed to identify risk factors associated with cardiac-specific death and AML-specific death. Results: A total of 64,679 AML patients were identified between 1973 and 2015; 68.48% of patients (44,292) received chemotherapy. Among all possible competing causes of death, AML was associated with the highest cumulative mortality. The AML patients who received chemotherapy showed excessive cardiac-specific mortality compared with the general population, with an SMR of 6.35 (95% CI: 5.89-6.82). Age, year of diagnosis, sex, and marital status were independently associated with patient prognosis. Conclusion: Cardiac-specific mortality in AML patients receiving chemotherapy is higher than that in the general population.

show abstract

Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010–2012 Medicare Limited Data Set

Abstract: AML in older patients is associated with frequent hospitalizations and intensive care unit admissions. New treatment options with more favorable risk-to-benefit profiles are needed in this population.

Cited by 9 publications

References 12 publications

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia

Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study

Long-term cardiac-specific mortality among 44,292 acute myeloid leukemia patients treated with chemotherapy: a population-based analysis

Contact Info

Product

Resources

About